Loading…
Alkermes plc is projected to rise to $45.87 by 2027, a +20% move from its current price of $38.09. ALKS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $37.40 | $38.11 | $38.83 | +0.04% |
| May 30 | $37.13 | $38.12 | $39.14 | +0.09% |
| May 31 | $36.92 | $38.14 | $39.39 | +0.13% |
| Jun 1 | $36.76 | $38.16 | $39.61 | +0.17% |
| Jun 2 | $36.61 | $38.17 | $39.80 | +0.22% |
| Jun 3 | $36.48 | $38.19 | $39.98 | +0.26% |
| Jun 4 | $36.36 | $38.21 | $40.14 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $36.36 | $38.21 | $40.14 | +0.30% |
| Week 2 | $35.73 | $38.32 | $41.10 | +0.61% |
| Week 3 | $35.28 | $38.44 | $41.88 | +0.91% |
| Week 4 | $34.92 | $38.55 | $42.56 | +1.22% |
| Week 5 | $34.62 | $38.67 | $43.19 | +1.52% |
| Week 6 | $34.36 | $38.79 | $43.78 | +1.83% |
| Week 7 | $34.13 | $38.90 | $44.34 | +2.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alkermes plc is a biopharmaceutical company that engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc (ALKS) is currently trading at $36.80.
The stock has a market capitalization of $6.13B and is ranked 1200.
The current price trajectory and the year-by-year forecast suggest upside potential over the longer term, with the average price forecast rising from $36.80 in 2026 to $74.78 in 2030 and to $405.71 in 2050.
From 2027 onward, the forecast shows continued bullish momentum, with 2027 avg $44.83, 2028 avg $51.18, 2029 avg $62.27, 2030 avg $74.78, 2031 avg $88.18, 2032 avg $94.17, 2033 avg $100.34, 2034 avg $114.47, 2035 avg $116.73, 2040 avg $199.05, and 2050 avg $405.71.
A major floor 28.6% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.2% away) — a breakout level to watch.
A major ceiling 11.4% above — clearing it would confirm fresh momentum.
Key ALKS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALKS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.23 | Buy | $37.44 | Buy |
| MA 10 | $37.51 | Buy | $37.15 | Buy |
| MA 20 | $36.29 | Buy | $36.40 | Buy |
| MA 50 | $33.87 | Buy | $34.60 | Buy |
| MA 100 | $32.64 | Buy | $33.08 | Buy |
| MA 200 | $31.01 | Buy | $31.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.70 | Neutral |
| Stoch RSI (14) | 48.51 | Neutral |
| CCI (20) | 84.45 | Neutral |
| Williams %R (14) | -20.92 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 8.86 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 79.08 | Neutral |
| TRIX (15) | 0.47 | Buy |
| Awesome (5,34) | 1.95 | Buy |
| Ultimate (7,14,28) | 65.85 | Neutral |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 37.26 | Buy |
| ADX (14) | 22.22 | Buy |
| ATR (14) | 0.58 | Info |
The 30-day technical picture is bullish. RSI14 is 60, signaling momentum that leans toward buying and upside potential in the near term.
The stock remains above key short-term moving averages: SMA50 at $33.47 and SMA200 at $30.90, suggesting a receptive stance to upside moves. Support sits at $33.22 while resistance is at $38.91, offering a defined path for near-term traders. The thirty-day range runs from $32.42 to $41.77, illustrating recent volatility within a constructive broader trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $27.20 | $38.09 | $52.55 | 0% | Neutral | |
| $37.47 | $45.87 | $58.77 | +20% | Bullish | |
| $41.97 | $52.31 | $68.78 | +37% | Bullish | |
| $50.10 | $63.39 | $85.08 | +66% | Bullish | |
| $58.89 | $75.51 | $103.13 | +98% | Bullish | |
| $68.96 | $89.49 | $124.13 | +135% | Bullish | |
| $72.74 | $95.44 | $134.26 | +151% | Bullish | |
| $76.00 | $100.77 | $143.57 | +165% | Bullish | |
| $86.15 | $115.36 | $166.29 | +203% | Bullish | |
| $87.10 | $117.73 | $171.58 | +209% | Bullish | |
| $140.96 | $198.69 | $303.37 | +422% | Bullish | |
| $266.62 | $402.97 | $659.37 | +958% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $27.20 | $38.09 | $44.48 | +0.00% |
| June 2026 | $32.80 | $38.26 | $45.50 | +0.46% |
| July 2026 | $33.77 | $39.62 | $47.56 | +3.54% |
| August 2026 | $34.07 | $40.15 | $48.55 | +1.34% |
| September 2026 | $33.98 | $40.20 | $48.90 | +0.12% |
| October 2026 | $34.98 | $41.52 | $50.78 | +3.29% |
| November 2026 | $35.98 | $42.84 | $52.63 | +3.17% |
| December 2026 | $35.67 | $42.58 | $52.55 | -0.59% |
Click any year to see its month-by-month ALKS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALKS to range from $27.20 to $52.55 through 2026. The $38.09 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ALKS price prediction for 2027 points to an average of $45.87 (low $37.47, high $58.77) — a potential gain of +20% on today's $38.09. Buyers look set to stay in control over this stretch.
In 2028, ALKS is projected to trade between $41.97 and $68.78, averaging $52.31 — a potential gain of +37% from today's $38.09. That is up +14% on the projected 2027 average. Momentum favours further upside here.
Alkermes plc's 2029 outlook centres on $63.39, within a $50.10 to $85.08 range. That is up +21% on the projected 2028 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ALKS could reach as high as $103.13, with a base case around $75.51 and support toward $58.89 — roughly +98% from $38.09. Momentum favours further upside here.
Expect ALKS to range from $68.96 to $124.13 through 2031. The $89.49 average target implies a +135% move from current prices. That is up +19% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ALKS price prediction for 2032 points to an average of $95.44 (low $72.74, high $134.26) — a potential gain of +151% on today's $38.09. Momentum favours further upside here.
In 2033, ALKS is projected to trade between $76.00 and $143.57, averaging $100.77 — a potential gain of +165% from today's $38.09. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Alkermes plc's 2034 outlook centres on $115.36, within a $86.15 to $166.29 range. That is up +14% on the projected 2033 average. That marks a +203% change versus current levels. Momentum favours further upside here.
By 2035, ALKS could reach as high as $171.58, with a base case around $117.73 and support toward $87.10 — roughly +209% from $38.09. Buyers look set to stay in control over this stretch.
Expect ALKS to range from $140.96 to $303.37 through 2040. The $198.69 average target implies a +422% move from current prices. That is up +69% on the projected 2035 average. Momentum favours further upside here.
The ALKS price prediction for 2050 points to an average of $402.97 (low $266.62, high $659.37) — a potential gain of +958% on today's $38.09. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALKS today (≈ 26.25361 ALKS) could be worth
$10,579.49
+$9,579.49 (+958%) by 2050 · US Dollar
Based on the average projected ALKS price of $402.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALKSwould be worth at today's price.
$1,000 invested in ALKS on May 27, 2025 (≈ 33.444816 ALKS) would be worth
$1,273.91
+$273.91 (+27.4%) today · 1.27× · US Dollar
Based on a ALKS entry price of $29.9 vs. today's $38.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $36.98 | $1,030.02 | +3.0% |
| 1 month ago | $33.73 | $1,129.26 | +12.9% |
| 3 months ago | $30.73 | $1,239.51 | +24.0% |
| 6 months ago | $29.58 | $1,287.69 | +28.8% |
| 1 year ago | $29.9 | $1,273.91 | +27.4% |
| All time (5.0y) ago | $23.15 | $1,645.36 | +64.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALKS forecast.
Our base-case forecast reaches $76.00 around 2031.
Implied market cap at $76.00: $12.67B
The multi-year forecast shows substantial upside over the longer horizon. The average forecast price rises from $36.80 in 2026 to $74.78 in 2030, then to $405.71 in 2050, with larger long-run upside reflected in the higher-end projections. The implied ROI compounds from 0% in 2026 to 21.8% in 2027, 39.1% in 2028, 69.2% in 2029, 103.2% in 2030, 139.6% in 2031, 155.9% in 2032, 172.7% in 2033, 211.1% in 2034, 217.2% in 2035, 440.9% in 2040, and 1002.5% in 2050.
The outlook is bullish across the longer term, though these are estimates and not guarantees, and depend on market conditions and company performance.
Tap a question to reveal the answer.
The forecast shows an average price of $74.78, with a min of $58.17, a max of $102.48, and a ROI of 103.2%, with bullish sentiment.
The long-run view is bullish, with rising average prices through 2050 (e.g., $74.78 in 2030 and $405.71 in 2050) and significant upside in later years (e.g., 2040 ROI 440.9% and 2050 ROI 1002.5%). These are estimates and not guarantees.
Yes. The 2030 max forecast is $102.48, and the 2031 max forecast is $122.75, indicating potential to exceed $100 in 2030 or 2031.
RSI14 is 60; SMA50 is $33.47; SMA200 is $30.90; support is $33.22 and resistance is $38.91. The thirty-day range is $32.42–$41.77, with a bullish overall sentiment.
Current price is $36.80 and market cap is $6.13B.
Alkermes plc Community Discussion
0Share your Alkermes plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.